187 related articles for article (PubMed ID: 35051209)
1. Results of a phase 1, randomized, placebo-controlled first-in-human trial of griffithsin formulated in a carrageenan vaginal gel.
Teleshova N; Keller MJ; Fernández Romero JA; Friedland BA; Creasy GW; Plagianos MG; Ray L; Barnable P; Kizima L; Rodriguez A; Cornejal N; Melo C; Cruz Rodriguez G; Mukhopadhyay S; Calenda G; Sinkar SU; Bonnaire T; Wesenberg A; Zhang S; Kleinbeck K; Palmer K; Alami M; O'Keefe BR; Gillevet P; Hur H; Liang Y; Santone G; Fichorova RN; Kalir T; Zydowsky TM
PLoS One; 2022; 17(1):e0261775. PubMed ID: 35051209
[TBL] [Abstract][Full Text] [Related]
2. Griffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV infections in vivo.
Derby N; Lal M; Aravantinou M; Kizima L; Barnable P; Rodriguez A; Lai M; Wesenberg A; Ugaonkar S; Levendosky K; Mizenina O; Kleinbeck K; Lifson JD; Peet MM; Lloyd Z; Benson M; Heneine W; O'Keefe BR; Robbiani M; Martinelli E; Grasperge B; Blanchard J; Gettie A; Teleshova N; Fernández-Romero JA; Zydowsky TM
Nat Commun; 2018 Sep; 9(1):3881. PubMed ID: 30250170
[TBL] [Abstract][Full Text] [Related]
3. Preformulation Characterization of Griffithsin, a Biopharmaceutical Candidate for HIV Prevention.
Kramzer LF; Hamorsky KT; Graebing PW; Wang L; Fuqua JL; Matoba N; Lasnik AB; Moncla BJ; Zhang J; Palmer KE; Rohan LC
AAPS PharmSciTech; 2021 Feb; 22(3):83. PubMed ID: 33625602
[TBL] [Abstract][Full Text] [Related]
4. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
[TBL] [Abstract][Full Text] [Related]
5. Griffithsin and Carrageenan Combination To Target Herpes Simplex Virus 2 and Human Papillomavirus.
Levendosky K; Mizenina O; Martinelli E; Jean-Pierre N; Kizima L; Rodriguez A; Kleinbeck K; Bonnaire T; Robbiani M; Zydowsky TM; O'Keefe BR; Fernández-Romero JA
Antimicrob Agents Chemother; 2015 Dec; 59(12):7290-8. PubMed ID: 26369967
[TBL] [Abstract][Full Text] [Related]
6. First-in-Human Trial of MIV-150 and Zinc Acetate Coformulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence, and Pharmacodynamics.
Friedland BA; Hoesley CJ; Plagianos M; Hoskin E; Zhang S; Teleshova N; Alami M; Novak L; Kleinbeck KR; Katzen LL; Zydowsky TM; Fernández-Romero JA; Creasy GW
J Acquir Immune Defic Syndr; 2016 Dec; 73(5):489-496. PubMed ID: 27437826
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of silk fibroin biomaterial vehicle for in vivo mucosal delivery of Griffithsin and protection against HIV and SHIV infection ex vivo.
Crakes KR; Herrera C; Morgan JL; Olstad K; Hessell AJ; Ziprin P; LiWang PJ; Dandekar S
J Int AIDS Soc; 2020 Oct; 23(10):e25628. PubMed ID: 33073530
[TBL] [Abstract][Full Text] [Related]
8. FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir.
Bunge KE; Dezzutti CS; Hendrix CW; Marzinke MA; Spiegel HML; Moncla BJ; Schwartz JL; Meyn LA; Richardson-Harman N; Rohan LC; Hillier SL
J Int AIDS Soc; 2018 Aug; 21(8):e25156. PubMed ID: 30101439
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection.
Marais D; Gawarecki D; Allan B; Ahmed K; Altini L; Cassim N; Gopolang F; Hoffman M; Ramjee G; Williamson AL
Antivir Ther; 2011; 16(8):1219-26. PubMed ID: 22155903
[TBL] [Abstract][Full Text] [Related]
10. Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention film (MB66): A Phase I randomized trial.
Politch JA; Cu-Uvin S; Moench TR; Tashima KT; Marathe JG; Guthrie KM; Cabral H; Nyhuis T; Brennan M; Zeitlin L; Spiegel HML; Mayer KH; Whaley KJ; Anderson DJ
PLoS Med; 2021 Feb; 18(2):e1003495. PubMed ID: 33534791
[TBL] [Abstract][Full Text] [Related]
11. Studies in a Murine Model Confirm the Safety of Griffithsin and Advocate Its Further Development as a Microbicide Targeting HIV-1 and Other Enveloped Viruses.
Kouokam JC; Lasnik AB; Palmer KE
Viruses; 2016 Nov; 8(11):. PubMed ID: 27869695
[TBL] [Abstract][Full Text] [Related]
12. In vitro Study on Synergistic Interactions Between Free and Encapsulated Q-Griffithsin and Antiretrovirals Against HIV-1 Infection.
Minooei F; Fried JR; Fuqua JL; Palmer KE; Steinbach-Rankins JM
Int J Nanomedicine; 2021; 16():1189-1206. PubMed ID: 33623382
[TBL] [Abstract][Full Text] [Related]
13. Impact of a new carrageenan-based vaginal microbicide in a female population with genital HPV-infection: first experimental results.
Perino A; Consiglio P; Maranto M; De Franciscis P; Marci R; Restivo V; Manzone M; Capra G; Cucinella G; Calagna G
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6744-6752. PubMed ID: 31378918
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
Justman JE; Nair GL; Hendrix CW; Piper JM; Marzinke MA; Dai JY; Pan Z; Galaska B; Levy L; Schwartz JL; Balar B; Kunjara Na Ayudhya RP; Mushamiri I; McGowan I; Dezzutti CS;
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):175-182. PubMed ID: 29767639
[TBL] [Abstract][Full Text] [Related]
15. In Vitro Exposure to PC-1005 and Cervicovaginal Lavage Fluid from Women Vaginally Administered PC-1005 Inhibits HIV-1 and HSV-2 Infection in Human Cervical Mucosa.
Villegas G; Calenda G; Zhang S; Mizenina O; Kleinbeck K; Cooney ML; Hoesley CJ; Creasy GW; Friedland B; Fernández-Romero JA; Zydowsky TM; Teleshova N
Antimicrob Agents Chemother; 2016 Sep; 60(9):5459-66. PubMed ID: 27381393
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial.
Keller MJ; Wood L; Billingsley JM; Ray LL; Goymer J; Sinclair S; McGinn AP; Marzinke MA; Frank B; Srinivasan S; Liu C; Atrio JM; Espinoza L; Mugo N; Spiegel HML; Anderson PL; Fredricks DN; Hendrix CW; Marrazzo J; Bosinger SE; Herold BC
Lancet HIV; 2019 Aug; 6(8):e498-e508. PubMed ID: 31320290
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial.
Skoler-Karpoff S; Ramjee G; Ahmed K; Altini L; Plagianos MG; Friedland B; Govender S; De Kock A; Cassim N; Palanee T; Dozier G; Maguire R; Lahteenmaki P
Lancet; 2008 Dec; 372(9654):1977-87. PubMed ID: 19059048
[TBL] [Abstract][Full Text] [Related]
18. Impact of the griffithsin anti-HIV microbicide and placebo gels on the rectal mucosal proteome and microbiome in non-human primates.
Girard L; Birse K; Holm JB; Gajer P; Humphrys MS; Garber D; Guenthner P; Noël-Romas L; Abou M; McCorrister S; Westmacott G; Wang L; Rohan LC; Matoba N; McNicholl J; Palmer KE; Ravel J; Burgener AD
Sci Rep; 2018 May; 8(1):8059. PubMed ID: 29795295
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women.
Nel AM; Coplan P; van de Wijgert JH; Kapiga SH; von Mollendorf C; Geubbels E; Vyankandondera J; Rees HV; Masenga G; Kiwelu I; Moyes J; Smythe SC
AIDS; 2009 Jul; 23(12):1531-8. PubMed ID: 19550287
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study.
O'Loughlin J; Millwood IY; McDonald HM; Price CF; Kaldor JM; Paull JR
Sex Transm Dis; 2010 Feb; 37(2):100-4. PubMed ID: 19823111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
